Mitochondrial dynamics, quality control, and mtDNA in alcohol-associated liver disease and liver cancer.
Mitochondria are intracellular organelles responsible for energy production, glucose and lipid metabolism, cell death, cell proliferation, and innate immune response.
APA
Ma X, Niu M, et al. (2026). Mitochondrial dynamics, quality control, and mtDNA in alcohol-associated liver disease and liver cancer.. Hepatology (Baltimore, Md.), 83(3), 639-660. https://doi.org/10.1097/HEP.0000000000000910
MLA
Ma X, et al.. "Mitochondrial dynamics, quality control, and mtDNA in alcohol-associated liver disease and liver cancer.." Hepatology (Baltimore, Md.), vol. 83, no. 3, 2026, pp. 639-660.
PMID
38683546
Abstract
Mitochondria are intracellular organelles responsible for energy production, glucose and lipid metabolism, cell death, cell proliferation, and innate immune response. Mitochondria are highly dynamic organelles that constantly undergo fission, fusion, and intracellular trafficking, as well as degradation and biogenesis. Mitochondrial dysfunction has been implicated in a variety of chronic liver diseases including alcohol-associated liver disease, metabolic dysfunction-associated steatohepatitis, and HCC. In this review, we provide a detailed overview of mitochondrial dynamics, mitophagy, and mitochondrial DNA-mediated innate immune response, and how dysregulation of these mitochondrial processes affects the pathogenesis of alcohol-associated liver disease and HCC. Mitochondrial dynamics and mitochondrial DNA-mediated innate immune response may thereby represent an attractive therapeutic target for ameliorating alcohol-associated liver disease and alcohol-associated HCC.
MeSH Terms
Humans; Liver Neoplasms; DNA, Mitochondrial; Mitochondrial Dynamics; Liver Diseases, Alcoholic; Mitophagy; Carcinoma, Hepatocellular; Immunity, Innate
같은 제1저자의 인용 많은 논문 (5)
- The tumor microenvironment as a key regulator of radiotherapy response.
- Genetic disruption of mitochondrial dynamics and stasis leads to liver injury and tumorigenesis.
- ALKBH5 facilitates acute myeloid leukemia development and immune escape via PD-L1 regulation.
- First-line PD-1 inhibitor plus chemotherapy improves outcomes in advanced gastric cancer and correlates with specific biomarkers in a real-world cohort.
- Immunohistochemical detection of PD-L1 in small cell lung cancer and its prognostic values.